Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency: Final appraisal document

In DRAFT guidance, NICE recommends nivolumab plus ipilimumab as an option for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency after fluoropyrimidine chemotherapy provided it is supplied according to commercial arrangements.

Source:

National Institute for Health and Care Excellence